Symptom frequency, severity lower after third SARS-CoV-2 mRNA vaccine vs. second in IBD

SAN DIEGO — Patients with inflammatory bowel disease experienced reduced symptom frequency and severity after a third SARS-CoV-2 mRNA vaccine compared with after a second, according to data presented at Digestive Disease Week 2022.“Our group and others have shown that symptoms after SARS-CoV-2 vaccination in those that receive primary vaccination with two doses of an mRNA vaccine in IBD are generally similar to the general population, and that symptoms after a second dose are more frequent and severe than after the first dose,” Angela Mujukian, MD, a postgraduate researcherRead More